<DOC>
	<DOCNO>NCT00004933</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . It yet know homoharringtonine effective hydroxyurea chronic myelogenous leukemia respond interferon alfa . PURPOSE : Randomized phase III trial compare effectiveness homoharringtonine hydroxyurea treat patient chronic myelogenous leukemia respond interferon alfa .</brief_summary>
	<brief_title>Homoharringtonine Compared With Hydroxyurea Chronic Myelogenous Leukemia That Has Not Responded Interferon Alfa</brief_title>
	<detailed_description>OBJECTIVES : I . Compare overall survival interferon alfa refractory chronic myelogenous leukemia patient treat homoharringtonine treat hydroxyurea . II . Compare time progression patient treat two drug . III . Estimate complete major cytogenetic response describe serial cytogenetics patient treat two drug . OUTLINE : This randomize study . Patients randomize receive one two treatment . Arm I : Induction : Patients receive homoharringtonine IV continuously 24 hour daily 14 day . Induction continue every 28 day maximum 6 course hematopoietic recovery . Maintenance : Patients receive homoharringtonine IV continuously 24 hour daily 5 day . Treatment repeat every 28 day . Arm II : Induction : Patients receive oral hydroxyurea daily 28 day acceptable blood count achieve . Maintenance : Patients receive oral hydroxyurea daily every 28 day maintain acceptable blood count . Treatment arm continue minimum 6 course absence disease progression unacceptable toxicity . Patients follow every 6 month maximum 10 year . PROJECTED ACCRUAL : A total 480 patient ( 240 per arm ) accrue study within 4 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Homoharringtonine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Harringtonines</mesh_term>
	<criteria>1 . Documentation Disease : 1.1 Diagnosis Chronic Myelogenous Leukemia ( CML ) chronic phase . Patients either accelerated blastic phase eligible . Clonal cytogenetic evolution alone exclude patient . See Appendix I definition accelerate blastic phase CML . 1.2 Patients Philadelphia chromosome [ ( 9 ; 22 ) ] detectable cytogenetic study eligible meet one follow criterion : BCR/ABL protein detectable immunoblotting BCR/ABL rearrangement detectable Southern blot analysis Polymerase chain reaction ( PCR ) positive fusion transcript BCR/ABL BCR/ABL translocation present fluorescence situ hybridization ( FISH ) . 2 . Prior Treatment : 2.1 No previous therapy homoharringtonine ( HHT ) 2.2 No six month cumulative ( &lt; 180 day ) prior hydroxyurea ( HU ) therapy . However , patient may receive 60 day HU treatment fail interferon . Patients previous intolerance failure respond HU eligible . 2.3 Patients must fail adequate trial ( 5M units/m2/day ) alphaInterferon ( IFN ) IFN/araC eligible , define ( ONE follow ) : Failure achieve complete hematologic response 6 month IFN therapy . Failure achieve cytogenetic response ( i.e. , still 100 % Ph+ ) 12 month IFN therapy . Intolerable adverse effect IFN therapy least one month IFN treatment . Significant document toxicity ≥ grade 3 ( use NCI Common Toxicity Criteria guideline ) due IFN require . Loss prior hematologic remission cytogenetic response IFN . A twofold increase WBC count compare WBC count IFN therapy initiate . 3 . Age ≥ 16 year 4 . Patients uncontrolled tachyarrhythmias ( , atrial fibrillation , paroxysmal supraventricular tachycardia , ventricular tachycardia adequately control ) eligible . 5 . Nonpregnant nonnursing . Treatment protocol would expose unborn child significant risk . Women men reproductive potential agree use effective mean birth control .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
</DOC>